The company confirmed this morning that NICE has taken the "unusual decision" to hold a third appraisal committee meeting as ...
NICE’s interim second draft guidance does not recommend lecanemab for use within the NHS in England and Wales at this time.
In what is seen as an unusual decision, the UK’s National Institute for Health and Care Excellence (NICE) says it will ...
Medpage Today on MSN21hOpinion
How a Book Is Undermining Progress Against Alzheimer'sSystematic fraud -- led by a "cabal of self-interested researchers, government accomplices, and corporate greed" in the words ...
President Donald Trump's nominee for NIH director, Dr Jay Bhattacharya, fielded intense questioning on vaccines and cuts to ...
A special edition of the journal Science focuses on women's health, including links between estrogen and dementia, at a time ...
GlobalData on MSN17h
Asceneuron halts Alzheimer’s trial adding to tau-targeting setbacksAfter Eli Lilly and Biogen’s setbacks in developing O-GlaNAcase (OGA) inhibitors for Alzheimer’s disease, Asceneuron has now ...
Lecanemab is an antibody infusion therapy, developed by pharmaceutical company Eisai, which has been shown to slow cognitive decline in the early stages of Alzheimer's disease. The drug is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback